Abbott ranked No. 9 on the Fair360 Top 50 Companies for Diversity list in 2023.
Abbott announced an agreement to acquire Bigfoot Biomedical, a leader in developing insulin management systems for people with diabetes.
Bigfoot Unity features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions to provide insulin dosing recommendations, which are displayed on the pen cap’s digital screen.
The pen caps help people know how much insulin they need to make, personalizing the process. The caps are the first and only FDA-cleared connected insulin pen caps.
The Bigfoot Unity system works with Abbott’s FreeStyle Libre technology and includes a smartphone app for customers to use and connect with their healthcare providers.
“The acquisition of Bigfoot Biomedical will combine two leaders in different aspects of diabetes care: continuous glucose monitoring and insulin dosing support,” said Jared Watkin, Senior Vice President of Abbott’s Diabetes Care business. “Bringing our companies together will allow us to further develop connected solutions for making diabetes management even more personal and precise.”
